Author

Emily A. Bossart 1

1 Cernostics, Inc.,Pittsburgh,United States

An automated, quantitative multiplex immunofluorescence assay accurately risk stratifies Barrett's esophagus patients with a community-based diagnosis of low-grade dysplasia at a rate comparable to expert pathologists

Nicola Frei, Kadère Konté, Emily A. Bossart, Yi Zhang, Rebecca J. Critchley-Thorne, Roos E. Pouw, Jacques J. Bergman

AN OBJECTIVE RISK PREDICTION ASSAY ACCURATELY RISK STRATIFIES BARRETT’S ESOPHAGUS PATIENTS WITH LOW-GRADE DYSPLASIA

Amir Khoshiwal, Nicola Frei, Kadère Konté, Roos E. Pouw, Kees A. Seldenrijk, G. Johan Offerhaus, John R. Goldblum, Fiebo Ten Kate, Jon M. Davison, Elizabeth Anne Montgomery, Emily A. Bossart, Rebecca J. Critchley-Thorne, Jacques J.G.H.M. Bergman

INDEPENDENT VALIDATION OF TISSUECYPHER TO PREDICT PROGRESSION IN COMMUNITY-BASED BARRETT'S ESOPHAGUS WITH LOW-GRADE DYSPLASIA: ANALYSIS IN A COMPLETED PROSPECTIVE STUDY

Nicola Frei, Amir Khoshiwal, Kadère Konté, Emily A. Bossart, Katelyn Stebbins, Zhang Yi, Roos E. Pouw, Fiebo J.W. ten Kate, Cornelis (Kees) A Seldenrijk, Sybren L. Meijer, Rebecca J. Critchley-Thorne, Jacques J.G.H.M. Bergman

Item 1 - 3 / 3
1